Search results
Results from the WOW.Com Content Network
Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant ...
Amgen (AMGN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AMGN earnings call for the period ending December 31, 2024. ... *Stock Advisor returns as of February 3, 2025. Robert A. Bradway-- Chairman and Chief Executive Officer.
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3] [4] As one of the world's largest independent biotechnology companies, Amgen has approximately 24,000 staff in total as of 2022.
Amgen (AMGN) closed at $224.46 in the latest trading session, marking a -1.43% move from the prior day.
Amgen (AMGN) closed the most recent trading day at $194.94, moving -0.23% from the previous trading session. Skip to main content. 24/7 Help. For premium support please call: 800-290 ...
In the latest trading session, Amgen (AMGN) closed at $247.45, marking a -0.3% move from the previous day.
Amgen (AMGN) closed the most recent trading day at $250.87, moving -0.46% from the previous trading session.